12.5% GAIN ON $BSX (BOSTON SCIENTIFIC) IN THE FACE OF SEVERAL BROKER DOWNGRADES
In spite of a negative article in Barron’s Online and two new broker downgrades, we have 12.5% gain at $7.10. This illustrates the power of
Unrivaled Performance In Bull And Bear Markets. FREE TRIALS.
|
Proven Track Record of Most Accurate Analysis
Proven Track Record
of Most Accurate Analysis
The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.
The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.
In spite of a negative article in Barron’s Online and two new broker downgrades, we have 12.5% gain at $7.10. This illustrates the power of
In ZYX Change Method, every trade must pass through six screens. In the first Change Screen, we are looking for macro changes. In this case,
www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD
www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD
www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD
$BSX is down substantially on FDA issues and competitors $MDT and $STJ have spiked up. These are minor paperwork issues and will not have a
We have been short with a very long term perspective on pharmacy benefit managers $MHS and $ESRX. The point of ZYX Change metod is all
Earlier today we sold $NFLX short at $71.20. Shortly afterwards $NFLX was touted as a buy because of Cisco announcement. Anyone following ZYX Change method